おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
ADC Therapeutics
company
About
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
- 251 - 500
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- Fr76M
- Industries
- Biopharma,Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 251 - 500
- Operating Status
- Active
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
Fr76M $385M
ADC Therapeutics has raised a total of
Fr76M $385M
in funding over 2 rounds. Their latest funding was raised on
Jun 12, 2019 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 12, 2019 | Series E | Fr76M | 1 | — | — | Detail |
| Oct 23, 2017 | Series E | $200M | 1 | — | — | Detail |
| Oct 27, 2016 | Series D | $105M | 1 | — | — | Detail |
| Sep 2, 2015 | Series C | $80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ADC Therapeutics is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
AstraZeneca
|
— | Series E |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
